Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O8BS
|
||||
| Former ID |
DCL000457
|
||||
| Drug Name |
AZD1656
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
AstraZeneca
|
||||
| Formula |
C24H26N6O5
|
||||
| InChI |
InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
|
||||
| InChIKey |
FJEJHJINOKKDCW-INIZCTEOSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Glucokinase | Target Info | Activator | [550288] | |
| KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
| Galactose metabolism | |||||
| Starch and sucrose metabolism | |||||
| Amino sugar and nucleotide sugar metabolism | |||||
| Butirosin and neomycin biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Insulin signaling pathway | |||||
| Insulin secretion | |||||
| Prolactin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Maturity onset diabetes of the young | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
| HIF-1-alpha transcription factor network | |||||
| References | |||||
| Ref 523091 | ClinicalTrials.gov (NCT01152385) Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients. U.S. National Institutes of Health. | ||||
| Ref 542677 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7701). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.